Cargando…

Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions

Cimifugin is a bioactive component of Saposhnikovia divaricata, a Chinese herb for treating allergy. Our previous studies demonstrated that cimifugin inhibited allergic inflammation efficiently. This study aims to determine the mechanism of cimifugin on epithelial cells in allergic inflammation. Mic...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaoyu, Jiang, Xiaoyan, Yu, Xi, Liu, Hailiang, Tao, Yu, Jiang, Guorong, Hong, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661257/
https://www.ncbi.nlm.nih.gov/pubmed/28597545
http://dx.doi.org/10.1111/jcmm.13204
_version_ 1783274451508396032
author Wang, Xiaoyu
Jiang, Xiaoyan
Yu, Xi
Liu, Hailiang
Tao, Yu
Jiang, Guorong
Hong, Min
author_facet Wang, Xiaoyu
Jiang, Xiaoyan
Yu, Xi
Liu, Hailiang
Tao, Yu
Jiang, Guorong
Hong, Min
author_sort Wang, Xiaoyu
collection PubMed
description Cimifugin is a bioactive component of Saposhnikovia divaricata, a Chinese herb for treating allergy. Our previous studies demonstrated that cimifugin inhibited allergic inflammation efficiently. This study aims to determine the mechanism of cimifugin on epithelial cells in allergic inflammation. Mice were sensitized and challenged with FITC to establish type 2 atopic dermatitis (AD) model. The initial stage of AD model, in which mice were just sensitized with FITC, was established in vivo and immortalized human epidermal (HaCaT) cells were utilized in vitro. Initiative key cytokines, TSLP and IL‐33, were measured by ELISA, the junctions in ECs were observed by electron microscopy and TJs (CLDN‐1, occludin and CLDND1) were assessed by Western blot, immunohistochemistry and immunofluorescence. The results showed that TSLP and IL‐33 were inhibited significantly by cimifugin in the initial stage of AD model. Simultaneously, cimifugin reduced the separated gap among the epithelial cells and increased the expression of TJs. Similar effects on TSLP/IL‐33 and TJs were obtained in vitro. The effect of cimifugin on TSLP decreased significantly when expression of CLDN1 was interfered with siRNA and this implied cimifugin inhibits initiative cytokines through restoring TJs. Furthermore, cimifugin administered only in the initial stage obviously attenuated the ultimate allergic inflammation, which indicate that impacts of cimifugin in the initial stage on TSLP/IL‐33 and TJs are sufficient for suppressing allergic inflammation. This study not only revealed the mechanisms of cimifugin, but also indicated the possibility of initiative key cytokines and TJs as therapeutic targets.
format Online
Article
Text
id pubmed-5661257
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56612572017-11-02 Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions Wang, Xiaoyu Jiang, Xiaoyan Yu, Xi Liu, Hailiang Tao, Yu Jiang, Guorong Hong, Min J Cell Mol Med Original Articles Cimifugin is a bioactive component of Saposhnikovia divaricata, a Chinese herb for treating allergy. Our previous studies demonstrated that cimifugin inhibited allergic inflammation efficiently. This study aims to determine the mechanism of cimifugin on epithelial cells in allergic inflammation. Mice were sensitized and challenged with FITC to establish type 2 atopic dermatitis (AD) model. The initial stage of AD model, in which mice were just sensitized with FITC, was established in vivo and immortalized human epidermal (HaCaT) cells were utilized in vitro. Initiative key cytokines, TSLP and IL‐33, were measured by ELISA, the junctions in ECs were observed by electron microscopy and TJs (CLDN‐1, occludin and CLDND1) were assessed by Western blot, immunohistochemistry and immunofluorescence. The results showed that TSLP and IL‐33 were inhibited significantly by cimifugin in the initial stage of AD model. Simultaneously, cimifugin reduced the separated gap among the epithelial cells and increased the expression of TJs. Similar effects on TSLP/IL‐33 and TJs were obtained in vitro. The effect of cimifugin on TSLP decreased significantly when expression of CLDN1 was interfered with siRNA and this implied cimifugin inhibits initiative cytokines through restoring TJs. Furthermore, cimifugin administered only in the initial stage obviously attenuated the ultimate allergic inflammation, which indicate that impacts of cimifugin in the initial stage on TSLP/IL‐33 and TJs are sufficient for suppressing allergic inflammation. This study not only revealed the mechanisms of cimifugin, but also indicated the possibility of initiative key cytokines and TJs as therapeutic targets. John Wiley and Sons Inc. 2017-06-09 2017-11 /pmc/articles/PMC5661257/ /pubmed/28597545 http://dx.doi.org/10.1111/jcmm.13204 Text en © 2017 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Wang, Xiaoyu
Jiang, Xiaoyan
Yu, Xi
Liu, Hailiang
Tao, Yu
Jiang, Guorong
Hong, Min
Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions
title Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions
title_full Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions
title_fullStr Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions
title_full_unstemmed Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions
title_short Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions
title_sort cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661257/
https://www.ncbi.nlm.nih.gov/pubmed/28597545
http://dx.doi.org/10.1111/jcmm.13204
work_keys_str_mv AT wangxiaoyu cimifuginsuppressesallergicinflammationbyreducingepithelialderivedinitiativekeyfactorsviaregulatingtightjunctions
AT jiangxiaoyan cimifuginsuppressesallergicinflammationbyreducingepithelialderivedinitiativekeyfactorsviaregulatingtightjunctions
AT yuxi cimifuginsuppressesallergicinflammationbyreducingepithelialderivedinitiativekeyfactorsviaregulatingtightjunctions
AT liuhailiang cimifuginsuppressesallergicinflammationbyreducingepithelialderivedinitiativekeyfactorsviaregulatingtightjunctions
AT taoyu cimifuginsuppressesallergicinflammationbyreducingepithelialderivedinitiativekeyfactorsviaregulatingtightjunctions
AT jiangguorong cimifuginsuppressesallergicinflammationbyreducingepithelialderivedinitiativekeyfactorsviaregulatingtightjunctions
AT hongmin cimifuginsuppressesallergicinflammationbyreducingepithelialderivedinitiativekeyfactorsviaregulatingtightjunctions